From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

Keytruda (pembrolizumab) is a brand-name IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects, such as eye ...

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Learn about cost, uses, and more of Keytruda ... It’s available only as a brand-name drug. Keytruda isn’t available in a biosimilar form. Biosimilars are like generic drugs.

Opdivo (nivolumab) and Keytruda (pembrolizumab) are brand-name biologic drugs prescribed for several types of cancer. They are given by a healthcare professional as an intravenous (IV) infusion.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

Keytruda comes only as a brand-name drug. There are no biosimilar forms available. Biosimilars are like generic drugs. Unlike generics, which are made for nonbiologic drugs, ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an analysis of MRK stock now.

Trodelvy, in combination with Merck’s immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new resu… ...

Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), and Merck (NYSE: MRK). Alphabet's problem isn't its financial results; in that ...

A decade later, this brand has entered 53 countries, is reimbursed in 68% of these markets, and has entered a new market at nearly the same rate as Keytruda, 64.5 days on average.

Pembrolizumab, brand name Keytruda, belongs to a class of immunotherapies called checkpoint inhibitors. The drug is an antibody designed to block PD-1, a protein on immune cells that keeps those ...